Activist investor Elliott builds stake in GSK after fresh trial upsetActivist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial Share XActivist investor Elliott builds stake in GSK after fresh trial upsethttps://pharmaphorum.com/news/activist-investor-elliott-builds-stake-in-gsk-after-fresh-trial-upset/
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
Romark eyes FDA okay for COVID antiviral despite mixed trial resultsA phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 Share XRomark eyes FDA okay for COVID antiviral despite mixed trial resultshttps://pharmaphorum.com/news/romark-eyes-fda-okay-for-covid-antiviral-despite-mixed-trial-results/
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of Share XPfizer/Myovant take relugolix contraceptive combination pill into phase 3https://pharmaphorum.com/news/pfizer-myovant-take-relugolix-contraceptive-combination-pill-into-phase-3/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
Akari begins late-stage trial of nomacopan for Bullous PemphigoidAkari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare Share XAkari begins late-stage trial of nomacopan for Bullous Pemphigoidhttps://pharmaphorum.com/news/akari-begins-late-stage-trial-of-nomacopan-for-bullous-pemphigoid/
South African variant may evade Pfizer/BioNTech vaccine, study findsThe coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted Share XSouth African variant may evade Pfizer/BioNTech vaccine, study findshttps://pharmaphorum.com/news/south-african-variant-may-evade-pfizer-biontech-vaccine-study-finds/
Regeneron’s antibody cocktail hits target in COVID prevention studyRegeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for Share XRegeneron’s antibody cocktail hits target in COVID prevention studyhttps://pharmaphorum.com/news/regeneron-to-ask-fda-to-c/
AstraZeneca’s Farxiga fails phase 3 COVID-19 testHope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed Share XAstraZeneca’s Farxiga fails phase 3 COVID-19 testhttps://pharmaphorum.com/news/astrazenecas-farxiga-fails-phase-3-covid-19-test/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
Lilly’s Olumiant flunks COVID-19 trial – or does it?Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 Share XLilly’s Olumiant flunks COVID-19 trial – or does it?https://pharmaphorum.com/news/lillys-olumiant-flunks-covid-19-trial-or-does-it/
Genmab CEO discusses repurposing cancer treatmentsGenmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, Share XGenmab CEO discusses repurposing cancer treatmentshttps://pharmaphorum.com/news/genmab-could-spin-out-autoimmune-disease-unit-says-ceo-goes-with-feature/
Safety study pushes back phase 3 trial of Newron’s schizophrenia drugSwitzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to Share XSafety study pushes back phase 3 trial of Newron’s schizophrenia drughttps://pharmaphorum.com/news/safety-trial-pushes-back-phase-3-trial-of-newrons-schizophrenia-drug/
FDA grew too close to Biogen during Alzheimer’s drug development, doctors sayThe FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its Share XFDA grew too close to Biogen during Alzheimer’s drug development, doctors sayhttps://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/
Novartis builds radio-oncology pipeline with iTheranostics dealNovartis has added to its pipeline of radiopharmaceuticals once again, licensing a series of agents from iTheranostics that Share XNovartis builds radio-oncology pipeline with iTheranostics dealhttps://pharmaphorum.com/news/novartis-builds-radio-oncology-pipeline-with-itheranostics-deal/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hopeTwo antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can Share XLilly and GSK/Vir antibody pairing offers resistant COVID-19 hopehttps://pharmaphorum.com/news/lilly-and-gsk-vir-antibody-pairing-offers-resistant-covid-19-hope/
